Mycoplasma agalactiae Vaccines: Current Status, Hurdles, and Opportunities Due to Advances in Pathogenicity Studies

Area of Science:

• Veterinary Microbiology
• Animal Health
• Infectious Diseases

Background:

• Contagious agalactia (CA) is a significant multietiological disease in livestock, primarily affecting goats and sheep.
• The classic etiological agent, Mycoplasma agalactiae, leads to high morbidity and mortality rates in herds.
• CA is a notifiable disease globally due to its substantial economic impact on the livestock industry.

Purpose of the Study:

• To review the limitations of current vaccines for contagious agalactia.
• To explore new vaccine development strategies for Mycoplasma agalactiae.
• To address challenges posed by antigenic variation and genomic plasticity in Mycoplasma agalactiae.

Main Methods:

• Literature review of existing vaccines and Mycoplasma agalactiae research.
• Analysis of virulence factors, particularly surface molecules involved in host interaction.
• Evaluation of epidemiological significance, including atypical strains in wildlife.

Main Results:

• Existing vaccines for contagious agalactia are few and largely inefficient.
• Antimicrobial therapy faces challenges due to intrinsic resistance and selection of resistant strains.
• Mycoplasma agalactiae's virulence relies on surface molecules, making them key targets for vaccine development.

Conclusions:

• There is a critical need for more effective vaccines against contagious agalactia.
• Future vaccine development must consider Mycoplasma agalactiae's antigenic variation and dynamic genome.
• Targeting surface molecules offers a promising avenue for developing novel and efficient vaccines.